Background: Depression is a common mental illness worldwide. Morita therapy is a novel and effective intervention method for treating depression patients. This study aimed to investigate the effects of modified Morita therapy on social functioning and quality of life in individuals suffering from depression.
Methods: The data of depressive patients hospitalized in Kangci Hospital of Jiaxing from June 2021 to May 2022 were collected and analyzed by propensity score matching (PSM). The control group received antidepressant treatment and standard psychiatric care (n = 30), while the study group received modified Morita therapy on the basis of standard treatment (n = 30). Both experimental groups received a six-week intervention. The 17-item Hamilton Depression Scale (HAMD-17) was used to assess the severity of depression before and after the intervention. Hamilton Anxiety Scale (HAMA) was used to assess the anxiety level of patients. Social Dysfunction Screening Scale (SDSS) was used to evaluate the social functioning of the patients. Generic Quality of Life Inventory-74 (GQOLI-74) was implemented to evaluate the quality of life of patients based on four dimensions: physical function, psychological function, social function, and material life status through 74 items.
Results: After six weeks of intervention, the study group exhibited significantly reduced HAMD-17, HAMA, and SDSS scores compared to the control group (p < 0.05). Furthermore, significant improvements were observed in physical function, psychological function, social function, material well-being domains, and the overall GQOLI-74 questionnaire scores within the study group compared to the control group (p < 0.05).
Conclusion: Modified Morita therapy effectively alleviates depression and anxiety levels among depressed patients while enhancing their social functioning and improving their quality of life, thus highlighting its clinical applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.62641/aep.v53i2.1714 | DOI Listing |
Actas Esp Psiquiatr
March 2025
Department of Rehabilitation, Kangci Hospital of Jiaxing, 314500 Tongxiang, Zhejiang, China.
Background: Depression is a common mental illness worldwide. Morita therapy is a novel and effective intervention method for treating depression patients. This study aimed to investigate the effects of modified Morita therapy on social functioning and quality of life in individuals suffering from depression.
View Article and Find Full Text PDFJ Pharmacol Sci
April 2025
Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, Tokyo, 108-8641, Japan. Electronic address:
Methylglyoxal (MGO), a highly reactive dicarbonyl compound produced via the glycolytic pathway, plays a key role in the pathogenesis of various diabetic complications, such as diabetic retinopathy. Müller cells provide neurotrophic support and maintain retinal homeostasis, including the redox balance. This dysfunction leads to retinal disease.
View Article and Find Full Text PDFJ Nippon Med Sch
March 2025
Department of Dermatology, Nippon Medical School.
Background: Psoriasis is accompanied by systemic inflammation that includes the liver. The fibrosis-4 (FIB-4) index was developed to predict significant liver fibrosis. The present study evaluated the effects of biologics, including TNF inhibitors, on the FIB-4 index in psoriasis patients.
View Article and Find Full Text PDFJ Gastroenterol
March 2025
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Background: Achieving complete response (CR) is a desirable goal in early-to-intermediate-stage hepatocellular carcinoma (HCC). While systemic and locoregional therapies show promise, optimal drug discontinuation criteria remain unclear. This study aims to investigate drug-off criteria for atezolizumab plus bevacizumab as a proof-of-concept study.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
March 2025
Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.
Background: Previous studies have shown comparable outcomes between first-generation high-dose drug-coated balloon (HD-DCB) and second-generation low-dose drug-coated balloon (LD-DCB) for femoropopliteal artery disease. However, data about the clinical performances of these DCBs for longer lesions in real-world clinical settings are limited.
Methods: In this multicenter, retrospective study, the clinical performances of the HD-DCB (IN.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!